Present Value of Free Cash Flow to the Firm (FCFF)
In discounted cash flow (DCF) valuation techniques the value of the stock is estimated based upon present value of some measure of cash flow. Free cash flow to the firm (FCFF) is generally described as cash flows after direct costs and before any payments to capital suppliers.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Intrinsic Stock Value (Valuation Summary)
Vertex Pharmaceuticals Inc., free cash flow to the firm (FCFF) forecast
US$ in thousands, except per share data
| Year | Value | FCFFt or Terminal value (TVt) | Calculation | Present value at |
|---|---|---|---|---|
| 01 | FCFF0 | |||
| 1 | FCFF1 | = × (1 + ) | ||
| 2 | FCFF2 | = × (1 + ) | ||
| 3 | FCFF3 | = × (1 + ) | ||
| 4 | FCFF4 | = × (1 + ) | ||
| 5 | FCFF5 | = × (1 + ) | ||
| 5 | Terminal value (TV5) | = × (1 + ) ÷ ( – ) | ||
| Intrinsic value of Vertex Pharmaceuticals Inc. capital | ||||
| Less: Finance lease liabilities (fair value) | ||||
| Intrinsic value of Vertex Pharmaceuticals Inc. common stock | ||||
| Intrinsic value of Vertex Pharmaceuticals Inc. common stock (per share) | ||||
| Current share price | ||||
Based on: 10-K (reporting date: 2024-12-31).
Disclaimer!
Valuation is based on standard assumptions. There may exist specific factors relevant to stock value and omitted here. In such a case, the real stock value may differ significantly form the estimated. If you want to use the estimated intrinsic stock value in investment decision making process, do so at your own risk.
Weighted Average Cost of Capital (WACC)
Vertex Pharmaceuticals Inc., cost of capital
| Value1 | Weight | Required rate of return2 | Calculation | |
|---|---|---|---|---|
| Equity (fair value) | ||||
| Finance lease liabilities (fair value) | = × (1 – ) |
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in thousands
Equity (fair value) = No. shares of common stock outstanding × Current share price
= ×
=
Finance lease liabilities (fair value). See details »
2 Required rate of return on equity is estimated by using CAPM. See details »
Required rate of return on debt. See details »
Required rate of return on debt is after tax.
Estimated (average) effective income tax rate
= ( + + + + ) ÷ 5
=
WACC =
FCFF Growth Rate (g)
FCFF growth rate (g) implied by PRAT model
Vertex Pharmaceuticals Inc., PRAT model
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
2 Interest expense, after tax = Interest expense × (1 – EITR)
= × (1 – )
=
3 EBIT(1 – EITR)
= Net income (loss) + Interest expense, after tax
= +
=
4 RR = [EBIT(1 – EITR) – Interest expense (after tax) and dividends] ÷ EBIT(1 – EITR)
= [ – ] ÷
=
5 ROIC = 100 × EBIT(1 – EITR) ÷ Total capital
= 100 × ÷
=
6 g = RR × ROIC
= ×
=
FCFF growth rate (g) forecast
Vertex Pharmaceuticals Inc., H-model
| Year | Value | gt |
|---|---|---|
| 1 | g1 | |
| 2 | g2 | |
| 3 | g3 | |
| 4 | g4 | |
| 5 and thereafter | g5 |
where:
g1 is implied by PRAT model
g5 is implied by single-stage model
g2, g3 and g4 are calculated using linear interpolation between g1 and g5
Calculations
g2 = g1 + (g5 – g1) × (2 – 1) ÷ (5 – 1)
= + ( – ) × (2 – 1) ÷ (5 – 1)
=
g3 = g1 + (g5 – g1) × (3 – 1) ÷ (5 – 1)
= + ( – ) × (3 – 1) ÷ (5 – 1)
=
g4 = g1 + (g5 – g1) × (4 – 1) ÷ (5 – 1)
= + ( – ) × (4 – 1) ÷ (5 – 1)
=